At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OSRH OSR Holdings
Post-Mkt 01-09 17:47:48 EST
0.6620
+0.0400
+6.43%
盘后0.6900
+0.0280+4.23%
16:34 EST
High0.7000Low0.6234Vol786.02K
Open0.6294D1 Closing0.6220Amplitude12.32%
Mkt Cap17.00MTradable Cap1.55MTotal Shares25.67M
T/O530.26KT/O Rate33.55%Tradable Shares2.34M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-OSR Holdings Says Woori IO Shareholders Approve Share Exchange To Become Unit Of Co
Reuters  ·  2025-12-20
BRIEF-OSR Holdings Says Woori IO Shareholders Approve Share Exchange To Become Unit Of Co
Woori IO Shareholders Approve Share Exchange with OSR Holdings
Reuters  ·  2025-12-20
Woori IO Shareholders Approve Share Exchange with OSR Holdings
Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of Osr Holdings
THOMSON REUTERS  ·  2025-12-20
Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of Osr Holdings
Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target
Reuters  ·  2025-12-05
Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target
Osr Holdings Inc - Vaximm Ag Shortens Exclusivity Period With Bcm Europe to Three Months
THOMSON REUTERS  ·  2025-12-02
Osr Holdings Inc - Vaximm Ag Shortens Exclusivity Period With Bcm Europe to Three Months
Vaximm AG Shortens Exclusivity Period With BCM Europe for Cancer Immunotherapy Deal
Reuters  ·  2025-12-02
Vaximm AG Shortens Exclusivity Period With BCM Europe for Cancer Immunotherapy Deal
OSR Holdings to Present Corporate Overview at Emerging Growth Conference
Reuters  ·  2025-12-02
OSR Holdings to Present Corporate Overview at Emerging Growth Conference
OSR Holdings’ Vaximm AG Enters Licensing Term Sheet
TIPRANKS  ·  2025-11-26
OSR Holdings’ Vaximm AG Enters Licensing Term Sheet
Vaximm AG Enters $835M License Term Sheet With BCM Europe for Cancer Immunotherapy
Reuters  ·  2025-11-25
Vaximm AG Enters $835M License Term Sheet With BCM Europe for Cancer Immunotherapy
OSR Holdings Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study
Reuters  ·  2025-11-25
OSR Holdings Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study
OSR Holdings’ Vaximm AG enters non-binding term sheet with BCM Europe
TIPRANKS  ·  2025-11-21
OSR Holdings’ Vaximm AG enters non-binding term sheet with BCM Europe
Vaximm Ag, an Osr Company, Enters Term Sheet With Bcm Europe for Potential Vxm01 License With $20M Upfront and up to $815M in Milestones
THOMSON REUTERS  ·  2025-11-21
Vaximm Ag, an Osr Company, Enters Term Sheet With Bcm Europe for Potential Vxm01 License With $20M Upfront and up to $815M in Milestones
Vaximm AG Enters $20M Term Sheet for VXM01 License Negotiations
Reuters  ·  2025-11-21
Vaximm AG Enters $20M Term Sheet for VXM01 License Negotiations
Vaximm AG Names Scientific Co-Founder Andreas Niethammer as CEO
Reuters  ·  2025-11-15
Vaximm AG Names Scientific Co-Founder Andreas Niethammer as CEO
Osr Holdings Appoints Scientific Co-Founder DR. Andreas Niethammer as Chief Executive Officer of Vaximm Ag to Lead Next Phase of Immuno-Oncology Expansion
THOMSON REUTERS  ·  2025-11-15
Osr Holdings Appoints Scientific Co-Founder DR. Andreas Niethammer as Chief Executive Officer of Vaximm Ag to Lead Next Phase of Immuno-Oncology Expansion
OSR Holdings Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $627.747K Miss $761.000K Estimate
Benzinga  ·  2025-11-13
OSR Holdings Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $627.747K Miss $761.000K Estimate
OSR Holdings Inc expected to post a loss of 12 cents a share - Earnings Preview
Reuters  ·  2025-11-08
OSR Holdings Inc expected to post a loss of 12 cents a share - Earnings Preview
OSR Holdings Reports High Accuracy in Woori IO Noninvasive Glucose Monitor Pilot Study
Reuters  ·  2025-11-06
OSR Holdings Reports High Accuracy in Woori IO Noninvasive Glucose Monitor Pilot Study
Osr Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study
THOMSON REUTERS  ·  2025-11-06
Osr Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study
OSR Holdings Inc. Files Initial Statement of Beneficial Ownership for Director Reto Kaspar Fierz
Reuters  ·  2025-10-25
OSR Holdings Inc. Files Initial Statement of Beneficial Ownership for Director Reto Kaspar Fierz

Introduction

Company Name.
OSR Holdings
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire companies in the healthcare industry. Bellevue Life Sciences Acquisition Corp. was founded in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.
Issue price:
--